Výsledky vyhledávání - "J. M. Brotchie"

Autor: R, Depoortere, T H, Johnston, S H, Fox, J M, Brotchie, A, Newman-Tancredi

Publikováno v: Parkinsonismrelated disorders. 78

Long-term treatment of Parkinson's disease (PD) with l-DOPA typically leads to development of l-DOPA induced dyskinesia (LID). Amantadine, an NMDA antagonist, attenuates LID, but with limited efficacy and considerable side-effects. NLX-112 (also know

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::452f275a718872e23fd39e30d57664d8
https://pubmed.ncbi.nlm.nih.gov/32846366

Zobrazit plný text záznamu

Role for vanilloid receptor 1 (TRPV1) and endocannabinoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats

Autor: J. Lee, V. Di Marzo, J. M. Brotchie

Publikováno v: Neuropharmacology (2006).
info:cnr-pdr/source/autori:J. Lee, V. Di Marzo and J. M. Brotchie/titolo:Role for vanilloid receptor 1 (TRPV1) and endocannabinoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats/doi:/rivista:Neuropharmacology/anno:2006/pagina_da:/pagina_a:/intervallo_pagine:/volume

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::42b6b24f724d84c8cd37335013f553c4
http://www.cnr.it/prodotto/i/15327

Zobrazit plný text záznamu

Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease

Autor: M P, Hill, C J, Hille, J M, Brotchie

Publikováno v: Drug newsperspectives. 13(5)

Current symptomatic treatments for Parkinson's disease are based largely on dopamine replacement therapies; however, the fact that these treatments are characterized by many long-term side effects has led to widespread interest in nondopaminergic the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0f8563e805ea54b766513f4d36a49ae2
https://pubmed.ncbi.nlm.nih.gov/12937640

Zobrazit plný text záznamu

Potential nondopaminergic drugs for Parkinson's disease

Autor: Monty A, Silverdale, S H, Fox, A R, Crossman, J M, Brotchie

Publikováno v: Advances in neurology. 91

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1db1a7658f1406f960e08e688de6a033
https://pubmed.ncbi.nlm.nih.gov/12442686

Zobrazit plný text záznamu

5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease

Autor: S H, Fox, J M, Brotchie

Publikováno v: Movement disorders : official journal of the Movement Disorder Society. 15(6)

The involvement of abnormalities in nondopaminergic transmitter systems in Parkinson's disease is noteworthy because of the complications, such as dyskinesia, associated with long-term dopamine replacement therapy. The output regions of the basal gan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9ac4b8f78ef3f206f3a0548d6c1abbba
https://pubmed.ncbi.nlm.nih.gov/11104187

Zobrazit plný text záznamu

The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease

Autor: J M, Brotchie

Publikováno v: Annals of neurology. 47(4 Suppl 1)

Treatment-related dyskinesias are the major limitation of dopamine replacement therapies such as levodopa in Parkinson's disease (PD). Recent studies in parkinsonian, nonhuman primates have highlighted abnormalities in neural functioning that might u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::02e72bca80d9a51512b96b8f999da8a4
https://pubmed.ncbi.nlm.nih.gov/10762137

Zobrazit plný text záznamu

The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat

Autor: M P, Hill, J M, Brotchie

Publikováno v: British journal of pharmacology. 128(7)

1. The treatment of Parkinson's disease relies predominantly upon dopamine replacement therapy, usually with l-dihydroxyphenylalanine (L-DOPA). However, side-effects of long-term treatment, such as L-DOPA-induced dyskinesias can be more debilitating

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a8dbc53e6eae12f5806f460e90646cee
https://pubmed.ncbi.nlm.nih.gov/10602339

Zobrazit plný text záznamu

Quantitative assessment of dyskinesias in subhuman primates

Autor: J M, Brotchie, S H, Fox

Publikováno v: Movement disorders : official journal of the Movement Disorder Society. 14

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ef04a7e49e49efc4a97dc0e467ca701a
https://pubmed.ncbi.nlm.nih.gov/10493402

Zobrazit plný text záznamu

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

Autor: B, Henry, S H, Fox, D, Peggs, A R, Crossman, J M, Brotchie

Publikováno v: Movement disorders : official journal of the Movement Disorder Society. 14(5)

Dopamine replacement therapy in patients with Parkinson's disease is plagued by the emergence of abnormal involuntary movements known as L-dopa-induced dyskinesias. It has been demonstrated that yohimbine can reduce L-dopa-induced dyskinesia in the M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::24e1805b10f6ebbc1f2e727394a5e923
https://pubmed.ncbi.nlm.nih.gov/10495035

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání